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Abstract
Background: The overall aim of presented study is to test the inhibition of the formation of collagen fibrils as the
novel approach to reduce accumulation of pathological fibrotic deposits. The main hypothesis is that by interfering
with the initial steps of the extracellular process of collagen fibril formation, it is possible to reduce the formation
of fibrotic tissue.
Methods: The experimental model includes antibody-based inhibitors that specifically bind to the sites that
participate in the collagen/collagen interaction.
Results: Employed antibody-based inhibitors effectively limit the amount of collagen fibrils formed in vitro and in
engineered tissue models of localized fibrosis.
Conclusions: (i) Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue.
(ii) Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit
localized fibrosis in a number of tissues.
Background
Collagen self-assembly
Collagen I is the most abundant structural protein of
connective tissues such as skin, bone, and tendon. This
protein is first synthesized as a precursor molecule, pro-
collagen, that is characterized by the presence of a rod-
like central triple-helical domain flanked by short linear
telopeptides and globular N-terminal and C-terminal
propeptides [1]. Single procollagen molecules are the
building blocks for the biologically-and mechanically-
relevant collagen fibrils (Figure 1). The formation of
collagen fibrils is initiated by enzymatic cleavage of N-
terminal and C-terminal propeptides. The N-terminal
propeptides are cleaved by a group of enzymes that
includes a disintegrin and metalloprotease with throm-
bospondin motifs (ADAMTS)-2, -3, and -14, while the
C-terminal propeptides are processed by the metallopro-
tease bone morphogenetic protein 1 (BMP-1) and by
the other members of a closely related family of mam-
malian tolloid-like metalloproteases [2-4]. Such removal
of procollagen propeptides exposes telopeptides, which
drive collagen self-assembly by engaging in site-specific
intermolecular interactions [5] (Figure 1, Figure 2, and
Figure 3A).
Collagen and fibrosis
In physiological conditions homeostasis of tissue col-
lagens is constantly maintained, but during a number of
pathological processes, the balance is shifted toward
fibrosis, a process of excessive collagen production and
accumulation. Fibrosis is a reactive process modulated by
various factors propagated by an inflammatory tissue
reaction. These factors trigger the local expansion of resi-
dent fibroblast subpopulations, modulate anabolic and
catabolic processes taking place in these cells, and influ-
ence reactions governing the biosynthesis and degrada-
tion of the connective tissue components. Contributing
to the metabolic modulation of the biosynthesis and
degradation of collagenous proteins are cytokines and
growth factors, a group of diverse molecules derived
from blood cells, such as platelets, or elaborated locally
by mesenchymal and epithelial cells [6].
Localized fibrotic reactions are quite common and fre-
quently develop as a consequence of trauma or surgical
procedures. For instance, after surgery of the abdomen,
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organs, such as the intestines, can interfere with the func-
tion of such organs and may cause severe pain and even
death. Another situation where excessive scar formation
presents a major complication is in the eye after glaucoma
surgery performed to create a pressure-maintenance valve.
Frequently, however, excessive scar formation closes this
pressure-reducing valve, thereby forcing the intraocular
pressure to rise [7]. Moreover, excessive scarring of the
vocal folds may severely alter their ability to vibrate,
thereby causing a number of voice disorders [8].
Inhibitors of fibrosis
At present, several biological processes critical for the
development of fibrotic lesions are considered potential
targets for inhibitors of fibrosis. These inhibitors aim at
(i) reducing inflammatory processes associated with
fibrosis, (ii) inhibiting biological functions of cytokines
and growth factors that promote fibrosis, (iii) reducing
cell proliferation, and (iv) decreasing the biosynthesis
and enzymatic processing of procollagen molecules. The
common characteristic of the above approaches is that
they target broad upstream processes of the fibrotic cas-
cade. Since most of these processes are involved not
only in pathological fibrosis, but also in a number of
physiological events, interfering with them is frequently
associated with adverse effects [9-13]. Below is a brief
characteristic of various clinical and experimental
approaches employed currently and in the past to
reduce localized fibrotic changes.
Inhibition of the inflammatory phase
Inhibition of excessive fibrosis at the inflammatory stage
has been widely investigated, and at present, is the most
established approach to scar management. The inflam-
matory response can be regulated before, during, and
after synthesis of the inflammatory mediators. The most
commonly applied anti-inflammatory agents targeting
production of inflammatory proteins are glucocortico-
steroids. These compounds are effective in some cases of
liver and pulmonary fibrosis and also in some patients
treated for severe hypertrophic scars of the skin
[11,14-17]. Because of the adverse side effects of steroids,
particularly when applied systemically, their use is limited
in chronic fibrotic diseases. Most nonsteroidal anti-
inflammatory drugs studied as antifibrotic agents were
reported to be ineffective [18].
Inhibition of cytokines
A number of cytokines and growth factors have been iden-
tified in fibrotic processes, and their roles have been asso-
ciated with the activation of the expression of genes
encoding collagens and other structural macromolecules.
Among these factors, members of the TGF-b family, con-
n e c t i v et i s s u eg r o w t hf a c t o r (CTGF), platelet derived
growth factor (PDGF), and epidermal growth factor (EGF)
play key roles. Perhaps the most attractive target for inhi-
biting fibrosis at the level of cytokines is TGF-b1. As
demonstrated by Shah et al., injecting anti-TGF-b1a n t i b o -
dies into margins of healing wounds significantly decreases
scar formation [13]. TGF-b,h o w e v e r ,h a sn o r m a lf u n c -
tions that make chronic administration of any inhibitor
that indiscriminately blocks TGF-b activity problematic
due to unwanted side effects. Moreover, the overall enthu-
siasm about using an anti-TGF-b1 approach to treat fibro-
s i si sh a m p e r e db ye v i d e n c et h a tT G F - b1 may also
function as a tumor suppressor [19,20]. The main concern,
then, is that long-term exposure to TGF-b1 inhibitors
could cause dangerous side-effects in the form of cancers.
Still, more recently approaches targeting TGF-b1v i a
blocking connexin-mediated mechanisms were proposed.
Figure 1 Electron microscopy of a single procollagen molecule
and a collagen fibril formed in vitro by self-assembly of
collagen molecules. A procollagen molecule, 300 nm in length,
consists of the triple-helical domain flanked with the N propeptide
and the C propeptide. Upon cleavage of the propeptides by specific
enzymes, collagen molecules self-assemble to form collagen fibrils.
Figure 2 Collagen/collagen interaction sites involved in fibril
formation. A, A schematic of collagen molecules interacting during
fibril formation. Sites that are involved in collagen/collagen binding
are indicated with red and blue boxes. These sites include the T-TBR
(a1 776-796 fragment) and the a2Ct. B, A computer model
representing interacting domains of two collagen molecules. The
triple-helical fragment of the T-TBR is indicated in blue, while the
fragment of the a2Ct of the interacting partner collagen molecule
is indicated in red. Amino acid residues most likely engaged in
collagen/collagen interaction are also indicated.
Steplewski and Fertala Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S29
http://www.fibrogenesis.com/content/5/S1/S29
Page 2 of 6Specifically, the studies showed that cell-permeable pep-
tides that block intracellular interactions of connexin 43
alter TGF-b1 functions, thereby limiting production of
collagen in an animal model [21]. A clinical value of this
intracellular approach, however, has not yet been
examined.
In addition to targeting TGF-b1 and other cytokines at
the protein level, attempts were made to inhibit the
expression of the corresponding genes by antisense oligo-
nucleotide or RNA interference (RNAi) approaches [22].
Although antisense oligonucleotide technology has been
around for about two decades, it appears that, for a variety
of reasons, this technology did not find a broad clinical
use and it is primarily employed as a research tool.
Inhibition of cell proliferation
Mitomycin-C and 5-fluorouracil inhibit the proliferation
of cells by blocking DNA synthesis and transcription. A
single application of these agents by injection was shown
to be effective in reducing the recurrence of keloid forma-
tion after surgery. Injection of 5-fluorouracil, however,
causes considerable pain, thereby limiting the use of this
agent for keloid reduction [12,23-25].
Inhibition of collagen synthesis
Because prolyl-4-hydroxylase-mediated post-translational
modifications are required for the correct folding of indivi-
dual pro-achains into functional triple-helical molecules
and for the secretion of such folded molecules into the
extracellular space, this enzyme was identified as a poten-
tial target to limit collagen biosynthesis. For instance,
“Doxorubicin”, a commonly used chemotherapeutic agent
that irreversibly inactivates prolyl-4-hydroxylase in human
skin fibroblasts, inhibits collagen chain assembly. It is not
clear, however, if this agent would be beneficial to patients
with excessive scar formation.
Yet another approach to limit the production of “func-
tional” collagen molecules was to administer proline
analogues [26]. Because proline is a major residue in
fibrillar collagens and constitutes ~10% of the total pool
of collagen amino acid residues, the rationale behind
this concept was that incorporating proline analogues to
newly synthesized collagen chains, instead of native
proline residues, would lead to the formation of non-
functional collagen molecules. Although a number of
proline analogues were developed a few decades ago, to
date, they have not been used due to significant toxic
side effects [26].
Inhibition of procollagen-processing enzymes
One of the critical steps that involved in collagen fibril for-
mation is the enzymatic cleavage of procollagen propep-
tides with procollagen N-proteinase (PNP) and BMP-1
[27,28]. The discovery of the amino acid sequence of
BMP-1 prompted the research on its potential inhibitors
[4,29,30]. The rationale of this approach was that
Figure 3 Collagen/collagen interaction sites involved in fibril formation; the basic concept of inhibiting collagen fibril formation. A, the
stages of normal fibril formation by site-specific interaction between telopeptides of one collagen molecule and the T-TBR of the interacting
molecule located in the D4 period; fibril-incorporated collagen molecules are very resistant to enzymatic degradation. B, by blocking the sites of
critical collagen-collagen interaction, formation of fibrils is inhibited, preventing the accumulation of fibrils and allowing rapid degradationo f
excess collagen molecules. Asterisks represent sites of cross-links formation. The model of a microfibril illustrates the compact packing of
collagen molecules (indicated in colors matching those for specific D periods) and indicates how the binding of a bulky inhibitor to collagen
molecules would prevent such a compact organization.
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BMP-1 would prevent fibril formation, thereby limiting
excessive fibrosis. Several inhibitors of BMP-1 (e.g. acidic
dipeptide hydroxamate) have been reported to be active in
vitro, but their effect on preventing collagen fibril forma-
tion is not known [9]. An additional significant problem is
that BMP-1, in addition to procollagens, processes a num-
ber of other macromolecules central to various important
biological events not related to collagen fibril formation
[31-35]. Moreover, BMP-1 knockout experiments demon-
strated the presence of normal collagen fibrils in tissues of
BMP-1-knockout mice, indicating that BMP-1 is not the
only enzyme able to process procollagen in vivo, making it
an unattractive target for inhibitors of fibrosis [35]. Simi-
larly, PNP knockout experiments demonstrated the pre-
sence of fully processed collagen I and collagen II in
tissues of experimental mice. Moreover, PNP knockout
caused sterility in males, an unexpected adverse effect [36].
Inhibition of formation of fibril-stabilizing cross-links
In physiological conditions, the chemical cross-linking of
collagen molecules incorporated in collagen fibrils is criti-
cal for the mechanical stability of fibrils. Moreover, the
presence of chemical cross-links makes fibril-incorporated
collagen molecules more resistant to proteolysis. This
notion is supported by a study which demonstrated that
long-term stability of free collagen molecules at 37°C is
quite low [37]. Because of such instability, exposed indivi-
dual a chains of these molecules are readily accessible to
proteases [37].
Formation of cross-links is an enzymatic process cata-
lyzed by lysyl-oxidase. Since lysyl oxidase is a copper-
dependent enzyme, it has been proposed that the use of
copper chelators, such as D-penicillamine, could result in
reduced cross-link formation, thereby limiting tissue fibro-
sis [38]. Postulations have also been made to employ b-
aminopropionitrile, a compound that inhibits enzymatic
activity of lysyl oxidase by irreversible binding to this
enzyme [38,39]. In a clinical context, however, inhibitors
of lysyl oxidase are not suitable for the treatment of fibro-
tic diseases because of their considerable toxicity.
Discussion
A novel concept; limiting tissue fibrosis by direct
targeting collagen fibril formation –
Because of a number of limitations of current approaches
to reduce excessive formation of localized fibrotic depos-
its, Chung et al. have proposed a novel concept. The pre-
mise of this new concept is that, regardless of etiology,
fibrotic deposits are built primarily from collagen, specifi-
cally collagen fibrils. Consequently, Chung et al.h a v e
proposed a plan to inhibit formation of fibrotic deposits
by limiting formation of collagen fibrils (Figure 2 and
Figure 3) [40].
In contrast to the approaches presented above, the
method proposed by Chung et al. targets a specific down-
stream event in a fibrotic cascade. Specifically, in this
novel approach, the main target is the collagen/collagen
interaction, a key process that drives collagen fibril forma-
tion (Figure 2, and Figure 3). The proposed target for inhi-
biting formation of collagen fibrils is well defined. It has
been determined that critical collagen/collagen binding is
mediated through interaction of the C-terminal a1(I) and
a2(I) telopeptides (a1Ct and a2Ct) of one collagen mole-
cule and the Triple-helical Telopeptide-Binding Region
(T-TBR) of another binding partner (Figure 2). It has been
also determined that the T-TBR corresponds to the a1
776-796 fragment of collagen I (Figure 2) [41]. Note: num-
bering of amino acid residues considers the first glycine
residue in a collagen triple-helical region as number “1”.
Even though collagen fibrils in vivo are complex hetero-
typic structures consisting not only of collagen I, but also
of other collagen types, such as collagen III and collagen
V, it is predicted that the novel approach targeting col-
lagen I self-assembly will still be effective. This notion is
justified because collagen I contributes the most to the
total protein mass of fibrotic tissue and other collagen
types are most effectively incorporated into a fibril only
when collagen I core is present [42]. Thus, by blocking the
self-assembly of collagen I, it will be possible to interrupt
the entire cascade of heterotypic fibril formation.
The prospect of the novel concept of inhibiting collagen
fibril formation by blocking collagen/collagen binding for
its clinical utility is supported, in part, by earlier reports
on the inhibition of intermolecular interactions. For
instance, the formation of amyloid fibrous deposits in
Alzheimer’s disease can be partially inhibited by a frag-
ment of collagenous Alzheimer amyloid plaque compo-
nent (CLAC), which blocks binding between full-length
CLAC molecules [43]. Moreover, a number of therapeutic
agents that act through blocking intermolecular interac-
tions already exist in the clinical practice. Those agents
include “Etanercept” (a fusion protein that neutralizes
soluble TNF-a in psoriasis, rheumatoid arthritis, and psor-
iatic arthritis) and “Enfuvirtide” (a synthetic peptide that
acts extracellularly and inhibits HIV entry into T cells).
These fundamental similarities among approaches to inhi-
bit various intermolecular interactions provide a valid
point in support of targeting collagen/collagen interaction
to limit excessive formation of collagen deposits.
Strategies of designing inhibitors of collagen fibril
formation
The original concept and the initial results on inhibiting
collagen fibril formation as a way to reduce the forma-
tion of fibrotic deposits in a keloid-like model were
described by Chung et al. [40]. In this study, the authors
have demonstrated that a monoclonal antibody that
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lagen I (anti-a2Ct) significantly reduces the amount of
collagen deposited in keloid-like constructs formed sub-
cutaneously in nude mice. The authors have concluded
that this reduction was a result of blocking the a2
C-terminal telopeptide-mediated collagen/collagen inter-
action (Figure 2) [40]. Based on the above results, utiliz-
ing antibody-based inhibitors is, at present, a leading
concept in an approach to reducing localized fibrosis
through interfering with collagen fibril formation. Anti-
body-based approaches include engineering clinically-
relevant IgG and scFv variants.
Conclusions
-Inhibition of collagen formation is an attractive target
to reduce excessive formation of fibrotic tissue.
-Unlike canonical inhibitors of excessive accumulation
of collagen-rich deposits, inhibition of collagen fibril for-
mation targets a specific, extracellular event.
-Blocking collagen fibril formation may serve as an
independent or supporting method to reduce excessive,
localized accumulation of collagen-rich deposits.
-Antibody-based inhibitors of collagen fibril formation
are promising therapeutic agents with a potential to
limit localized fibrosis in a number of tissues.
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